1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6BD4C10B07B72B82F0025859F0055F224
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-how-medical-affairs-teams-use-RWE-data-collection-roles?opendocument
18
19opendocument
2054.236.35.159
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Medical Affairs Data Management and Biostatics

How Medical Affairs Teams Use RWE: Data Collection and Roles

ID: 5623


Features:

11 Info Graphics

13 Data Graphics

100+ Metrics

5 Narratives


Pages/Slides: 30


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "How Medical Affairs Teams Use RWE: Data Collection and Roles"

STUDY OVERVIEW

The power of real world evidence (RWE) has significantly increased demand for outcomes and other RWE insights across the entire healthcare value chain, from thought leaders and HCPs to payers and regulatory bodies.

In response, pharmaceutical and medical device companies are taking steps to increase the precision and speed of their RWE capabilities. This trend has impacted Medical Affairs since pharma is relying on this function to lead and guide many aspects of RWE utilization.

This study evaluates the role of Medical Affairs in real world data collection and evaluation. It also examines the roles and responsibilities of Medical Affairs in RWE. This study will inform Medical Affairs leaders regarding the current trends and practices of medical regarding RWE generation and governance.

KEY TOPICS

  • Executive Summary
  • Real World Evidence in 2020 and Beyond
  • Real World Data – Collection & the Total Data Package
  • Medical Affairs Teams, Roles, & Responsibilities

KEY METRICS

1. Real World Data – Collection & the Total Data Package

  • Percentage of companies using different sources of real world data
  • Percentage change in use of specific sources of real world data from 2017 to 2020
  • Change in proportion of external and internal RWD collected from 2017 to 2020
  • Challenges faced by Medical Affairs in collecting and evaluating the use of real world data
  • Sources of internal and external real world data
  • Challenges faced by Medical Affairs groups of large companies in collecting and evaluating the use of real world data
  • Challenges faced by Medical Affairs groups of small-mid size companies in collecting and evaluating the use of real world data

2. Medical Affairs Teams, Roles, & Responsibilities
  • Real world data/evidence governance structure within benchmark companies
  • Reporting structure for Medical Affairs real world data/evidence team
  • Primary and secondary collaborators of Medical Affairs as part of its real world data/evidence program
  • Lead, co-lead and support roles of Medical Affairs function in various aspects of the real world data/evidence program
  • Core members of the medical-based RWE leadership group
  • Contribution of the medical teams in RWE leadership group across the RWE cycle


SAMPLE KEY FINDINGS
  • Leadership/Governance/Teams: Medical leadership/Co-leadership across RWE processes is essential for ensuring the medical and clinical value story are prominent internally and externally. Across compositions, a majority of medical-RWE teams report solely to medical executives.

METHODOLOGY

Best Practices engaged 45 industry leaders across 36 companies to discern RWD/E best practices, trends, and Medical Affairs optimal role.

Industries Profiled:
Pharmaceutical; Health Care; Medical Device; Biotech; Biopharmaceutical; Clinical Research; Laboratories


Companies Profiled:
Novartis; Merck; EMD Serono; Roche; AstraZeneca; Astellas; Merck Serono; Takeda Pharmaceuticals; Sanofi; Boehringer Ingelheim; Teva Pharmaceutical Industries Ltd; Eisai; Jazz Pharmaceuticals; Grifols; Edwards Lifesciences; OTSUKA; Vertex Pharmaceuticals; Terumo Corporation; UCB Pharma; Avanos Medical; GE Healthcare; Fidia; Intercept; CSPC Pharmaceutical Group; Invitae; Cipla; Proteus Digital Health; Agios; Almirall; Adamas Pharmaceuticals; Dendreon; Purdue Pharma; Searle; ADC Therapeutics; Mitsubishi Tanabe Pharma; Melinta Therapeutics; Inc

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.